We are proud of our HEDI special issue, part 1!
(Health Equity, Diversity, and Inclusion)
It is now online at: https://redjournal.org/issue/S0360-3016(23)X0004-2
Podcast for May 1, 2023 at: https://redjournal.org/pb-assets/Health%20Advance/journals/rob/116_1_May_1_2023_Highlights-1681312004100.mp3
#threegoodthings #3goodthings
1. I get to have amazing #IJROBP podcast conversations every few weeks with the smartest docs in #radonc talking about the things that make them most passionate. #BIGGOODTHING #LISTENUP #IJROBP #PODCAST
2. Always love the weekends.
3. Great hand lotion. Truly did not appreciate how important it was before COVID era handwashing.
#ThreeGoodThings #3goodthings #IJROBP #radonc #biggoodthing #listenup #podcast
#radonc #ONCOLOGY
Just issued -- Call for Papers!
#redjournal #IJROBP
"New Approaches to Combinatorial Therapy"
Deadline: August 15, 2023
#radonc #oncology #redjournal #IJROBP
Super thoughtful essay on the development of a health equity-centric approach to development of proton beam #radiation services in Canada.
It's a striking reflection -- in contrast to the U.S. 😢 -- of Canada's deep commitment to health equity.
At: https://www.redjournal.org/article/S0360-3016(22)03642-2/fulltext
#radonc #oncology #IJROBP #radiation
Very pleased to announce that we've finally gotten a long-awaited project completed, which is to assign DOI (digital object identifier) numbers to our podcasts.
If you'd like to reference one of the #IJROBP podcasts, now you can! They are published material recognized with permanent DOIs.
The future of publishing is digital!
Don't put the CART before the horse: The role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-Hodgkin lymphoma
retrospective review of 83 patients --> 1 year local control rate for bridging radiotherapy before CART 84% vs salvage radiotherapy after CART 62%
comprehensive salvage RT had better overall survival 51% vs. 12% and freedom from subsequent progression 31% vs. 0% than focal salvage RT
At: https://www.redjournal.org/article/S0360-3016(22)03637-9/fulltext
Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer
Of the 26/452 patients with feeding tubes at 10 years post-treatment, 8 were in place at baseline
p16+ patients had 5- and 10-year overall survival rate of 81.4% and 67.8%, compared to 50% and 33% for p16-
At: https://www.redjournal.org/article/S0360-3016(22)03636-7/fulltext
The #IJROBP podcast for January 1, 2023 focuses on Frontiers in Radiosurgery for Functional and Benign Conditions.
Includes Drs. Scott Soltys from Stanford, Daniel Trifiletti from Mayo Clinic Florida, and Valentina Pinzi from the the Neurological Institute Carlo Besta in Milan. Learn more about these emerging new areas in #radonc!
Podcast direct link: https://www.redjournal.org/pb-assets/Health%20Advance/journals/rob/115_1_January_1_2023_Highlights-1671028779137.mp3
#IJROBP podcast for January 2023 focuses on new emerging indications for benign and functional brain radiosurgery.
Includes Scott Soltys from Stanford, Dan Trifiletti from Mayo Clinic Florida, and Valentina Pinzi from the Neurological Institute Carlo Besta in Milan. Gain insights into this expanding area of #radonc from these world experts.
Check out the January 2023 issue of #IJROBP, now out online.
Featuring: functional and benign #radiosurgery, #meded reform, payment policy in cancer care, a primer on #radiopharm, #COVID19 departmental response, genetic profiling of #breastcancer and #prostatecancer, #radiation techniques for breast, prostate, #pediatric, #gastrointestinal, and #headandneck cancers, #clinicaltrials, trials of #medphys role in #radonc care, and many interesting letters to the editor.
#IJROBP #radiosurgery #MedEd #radiopharm #COVID19 #breastcancer #ProstateCancer #radiation #pediatric #gastrointestinal #headandneck #clinicaltrials #medphys #radonc
:LINAC:
Big kudos to #ASTRO for opening up their process for #ASTRO23 and providing a public link for the session submission site!
http://ow.ly/wvqa50LzXI4
Chrome or Firefox browser recommended.
In my experience, #ASTRO likes to see a reasonable number of speakers (3-4 +/- moderator) and a diversity of speakers and institutions. Good luck with your session submissions! Please consider whether you might be able to turn them into an #IJROBP review!
#DEIinRO #MedPhys #RadBio #radonc
:LINAC:
#ASTRO #ASTRO23 #IJROBP #DEIinRO #medphys #radbio #radonc